(Q35199632)

7 August 2017

Metabolic consequences of atypical antipsychotic drugs (English)

1 reference

7 August 2017

Harold E Lebovitz

1

1 reference

7 August 2017

1 January 2003

1 reference

7 August 2017

Psychiatric Quarterly

1 reference

7 August 2017

74

1 reference

7 August 2017

3

1 reference

7 August 2017

277-290

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1024170622266

7 August 2017

0 references

cites work

Olanzapine increases weight and serum triglyceride levels.

1 reference

12 December 2020

Diabetic ketoacidosis with olanzapine treatment

1 reference

12 December 2020

Diabetes mellitus in schizophrenic patients

1 reference

12 December 2020

Beta cell monoamines: further evidence for their role in modulating insulin secretion.

1 reference

12 December 2020

Hyperglycemia and antipsychotic medications.

1 reference

12 December 2020

Potentiation of insulin secretion in vitro by serotonin antagonists.

1 reference

12 December 2020

Weight gain associated with neuroleptic medication: a review

1 reference

12 December 2020

New onset diabetes and atypical antipsychotics

1 reference

12 December 2020

Fatality from olanzapine induced hyperglycemia.

1 reference

12 December 2020

Risperidone-associated new-onset diabetes

1 reference

12 December 2020

Olanzapine-induced elevation of plasma triglyceride levels

1 reference

12 December 2020

[Hyperglycemia and ketoacidosis associated with olanzapine]

1 reference

12 December 2020

Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents

1 reference

12 December 2020

Clozapine-associated elevation in serum triglycerides

1 reference

12 December 2020

Clozapine and associated diabetes mellitus

1 reference

12 December 2020

Hyperinsulinemia in psychiatric patients treated with olanzapine

1 reference

12 December 2020

Relative weight gain among antipsychotics

1 reference

12 December 2020

Atypical antipsychotics and hyperglycaemia

1 reference

12 December 2020

Novel antipsychotics: comparison of weight gain liabilities.

1 reference

12 December 2020

The effect of clozapine on glucose metabolism.

1 reference

12 December 2020

Lipids and apolipoproteins in patients treated with major tranquilizers

1 reference

12 December 2020

Clozapine-associated diabetes

1 reference

12 December 2020

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

1 reference

12 December 2020

Olanzapine-associated diabetes mellitus

1 reference

12 December 2020

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

1 reference

12 December 2020

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

12 December 2020

Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.

1 reference

12 December 2020

Effects of atypical antipsychotics on weight and serum lipid levels

1 reference

12 December 2020

New-onset diabetes mellitus associated with the initiation of quetiapine treatment

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Novel antipsychotics and severe hyperlipidemia

1 reference

12 December 2020

Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.

1 reference

12 December 2020

Ketoacidosis as a side-effect of clozapine: a case report

1 reference

12 December 2020

Serum triglyceride levels in patients treated with clozapine

1 reference

12 December 2020

Novel antipsychotics and new onset diabetes

1 reference

12 December 2020

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

12 December 2020

Diabetic ketoacidosis associated with risperidone treatment?

1 reference

12 December 2020

A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year

1 reference

12 December 2020

Prevalence and correlates of diabetes in national schizophrenia samples.

1 reference

12 December 2020

A short survey on untoward effects of fluperlapine

1 reference

12 December 2020

Hyperglycemia and olanzapine

1 reference

12 December 2020

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1024170622266

1 reference

PubMed ID

12918602

Dimensions Publication ID

7 August 2017

0 references

1 reference

PubMed ID

12918602